A Phase 3 interventional study of collagenase clostridium histolyticum in Advanced Dupuytren's Disease, sponsored by Endo Pharmaceuticals. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-02.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a Phase 3, 9-month, open-label study conducted in the United States. Subjects with a diagnosis of advanced Dupuytren's disease in a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint that resulted in a fixed flexion deformity of at least one finger, other than the thumb, that was at least 20° as measured by finger goniometry and was suitable for evaluation and injection were enrolled.
This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 (NCT00528606) and AUX-CC-859 (NCT00533273)) and 7 non-pivotal studies were evaluated.
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biological: collagenase clostridium histolyticum
Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.
Also known as: XIAFLEX®, AA4500
Reduction in Contracture to 5° or Less
The Primary Outcome Measure is the percentage of joints that were successfully treated where "successfully treated" was defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection
Time frame: Within 30 days after the last injection
Clinical Improvement After the Last Injection
Clinical Improvement is defined as \>=50% percent reduction from baseline in degree of contracture within 30 days after injection.
Time frame: Baseline; within 30 days after last injection
Percent Reduction From Baseline Contracture After the Last Injection
Percent change in degree of contracture measured as 100\*(baseline contracture -last available post-injection contracture)/baseline contracture)
Time frame: Baseline, within 30 days after last injection
Change From Baseline Range of Motion After the Last Injection
Change in degree of range of motion measured as last available post-injection range of motion - baseline range of motion.
Time frame: Baseline, 30 days after last injection
Time to Reach Clinical Success
Clinical success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection, displayed in post-injection timepoint categories.
Time frame: First evaluation visit on which clinical success is achieved through the Day 30 evaluation
Clinical Success After the First Injection
Clinical Success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection.
Time frame: Within 30 days after first injection
Clinical Improvement After the First Injection
Clinical Improvement is defined as \>=50% reduction from baseline in the degree of contracture within 30 days after the first injection
Time frame: Baseline; within 30 days after first injection
Percent Reduction From Baseline Contracture After the First Injection
Percent change in degree of contracture is measured as 100\* (baseline contracture- last available post-injection contracture)/baseline contracture.
Time frame: Baseline; within 30 days after first injection
Change From Baseline Range of Motion After the First Injection
Change in degree of range of motion measured as last available post-injection range of motion-baseline range of motion.
Time frame: Baseline; within 30 days after first injection
| Milestone | AA4500 0.58 mg |
|---|---|
| Started | 201 |
| Completed | 168 |
| Not completed | 33 |
| Withdrew: Lost to follow-up | 10 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 17 |
| Withdrew: Death | 2 |
| Withdrew: Administrative reasons | 1 |
| Withdrew: Other | 2 |
The Primary Outcome Measure is the percentage of joints that were successfully treated where "successfully treated" was defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection
| percentage of joints | AA4500 0.58 mg |
|---|---|
| Reduction in Contracture to 5° or Less | 52.7 |
Clinical Improvement is defined as \>=50% percent reduction from baseline in degree of contracture within 30 days after injection.
| percent of joints | AA4500 0.58 mg |
|---|---|
| Clinical Improvement After the Last Injection | 71.6 |
Percent change in degree of contracture measured as 100\*(baseline contracture -last available post-injection contracture)/baseline contracture)
| percentage of joints | AA4500 0.58 mg |
|---|---|
| Percent Reduction From Baseline Contracture After the Last Injection | 66.8 ± 40.91 |
Change in degree of range of motion measured as last available post-injection range of motion - baseline range of motion.
| degrees | AA4500 0.58 mg |
|---|---|
| Change From Baseline Range of Motion After the Last Injection | 28.3 ± 20.15 |
Clinical success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection, displayed in post-injection timepoint categories.
| percentage of joints | AA4500 0.58 mg |
|---|---|
| Injection 1, Day 1 | 9.6 |
| Injection 1, Day 7 | 16.4 |
| Injection 1, Day 30 | 16.1 |
| Injection 2, Day 0 | 0.0 |
| Injection 2, Day 1 | 2.4 |
| Injection 2, Day 7 | 2.4 |
| Injection 2, Day 30 | 3.1 |
| Injection 3, Day 0 | 0.0 |
| Injection 3, Day 1 | 0.7 |
| Injection 3, Day 7 | 1.0 |
| Injection 3, Day 30 | 0.7 |
| Injection 3, Day 90 | 0.3 |
| Did not reach clinical success | 47.3 |
Clinical Success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection.
| percentage of joints | AA4500 0.58 mg |
|---|---|
| Clinical Success After the First Injection | 42.5 |
Clinical Improvement is defined as \>=50% reduction from baseline in the degree of contracture within 30 days after the first injection
| percentage of joints | AA4500 0.58 mg |
|---|---|
| Clinical Improvement After the First Injection | 64.4 |
Percent change in degree of contracture is measured as 100\* (baseline contracture- last available post-injection contracture)/baseline contracture.
| percentage of change | AA4500 0.58 mg |
|---|---|
| Percent Reduction From Baseline Contracture After the First Injection | 60.4 ± 39.38 |
Change in degree of range of motion measured as last available post-injection range of motion-baseline range of motion.
| degrees | AA4500 0.58 mg |
|---|---|
| Change From Baseline Range of Motion After the First Injection | 25.3 ± 19.52 |
Collected over Non-serious adverse events (non-SAEs) were collected from time of study drug administration, serious adverse events (SAEs) were collected from time subject signed ICF. Non-SAEs & SAEs were collected until 30 days after completion or discharge from study.. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AA4500 0.58 mg | — | 11/201 (5.5%) | 197/201 (98%) |
| Event | AA4500 0.58 mg |
|---|---|
| Myocardial infarctionCardiac disorders | 2/201 |
| Acute myocardial infarctionCardiac disorders | 1/201 |
| Atrial fibrillationCardiac disorders | 1/201 |
| Chest painGeneral disorders | 1/201 |
| Clavicle fractureInjury, poisoning and procedural complications | 1/201 |
| Compression fractureInjury, poisoning and procedural complications | 1/201 |
| Deep vein thrombosisVascular disorders | 1/201 |
| EmbolismVascular disorders | 1/201 |
| Enterococcal sepsisInfections and infestations | 1/201 |
| FallInjury, poisoning and procedural complications | 1/201 |
| Event | AA4500 0.58 mg |
|---|---|
| Oedema peripheralGeneral disorders | 151/201 |
| Injection site painGeneral disorders | 116/201 |
| Injection site haemorrhageGeneral disorders | 109/201 |
| ContusionInjury, poisoning and procedural complications | 100/201 |
| Injection site swellingGeneral disorders | 57/201 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 48/201 |
| TendernessGeneral disorders | 48/201 |
| EcchymosisSkin and subcutaneous tissue disorders | 43/201 |
| Skin lacerationInjury, poisoning and procedural complications | 32/201 |
| PruritusSkin and subcutaneous tissue disorders | 24/201 |
| Age, Categorical(Participants) | AA4500 0.58 mg |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 95 |
| >=65 years | 106 |
| Age, Continuous(years) | AA4500 0.58 mg |
|---|---|
| Mean | 64.7 ± 9.86 |
| Sex: Female, Male(Participants) | AA4500 0.58 mg |
|---|---|
| Female | 37 |
| Male | 164 |
| Race/Ethnicity, Customized(participants) | AA4500 0.58 mg |
|---|---|
| White | 201 |
| Region of Enrollment(participants) | AA4500 0.58 mg |
|---|---|
| United States | 201 |
Ran from Oct 2007 to primary completion in Oct 2008, 12 months.
Results were first posted in Oct 2010, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase